Published in Oncogene on February 26, 2007
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov (2009) 10.32
p53 and metabolism. Nat Rev Cancer (2009) 5.05
Redox regulation of cell survival. Antioxid Redox Signal (2008) 4.33
p53 dynamics control cell fate. Science (2012) 3.30
Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol (2010) 3.28
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci U S A (2009) 3.04
Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol (2012) 2.53
HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase. Nature (2010) 2.23
The ups and downs of p53: understanding protein dynamics in single cells. Nat Rev Cancer (2009) 2.13
The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev (2008) 2.06
Stimulus-dependent dynamics of p53 in single cells. Mol Syst Biol (2011) 2.02
Metabolic regulation by p53 family members. Cell Metab (2013) 2.00
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
The multiple levels of regulation by p53 ubiquitination. Cell Death Differ (2010) 1.87
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
SnapShot: p53 posttranslational modifications. Cell (2008) 1.75
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest (2011) 1.59
The in vivo gene expression signature of oxidative stress. Physiol Genomics (2008) 1.55
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ (2013) 1.50
Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc Natl Acad Sci U S A (2009) 1.50
Sensitivity of salivary glands to radiation: from animal models to therapies. J Dent Res (2009) 1.43
Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep (2013) 1.43
Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure (2010) 1.39
5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep (2013) 1.37
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol (2010) 1.33
Crystal structure of a p53 core tetramer bound to DNA. Oncogene (2008) 1.28
Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol (2009) 1.28
Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell (2011) 1.27
Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol (2008) 1.27
Surf the post-translational modification network of p53 regulation. Int J Biol Sci (2012) 1.25
Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J (2011) 1.24
The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol (2010) 1.23
Mouse models of p53 functions. Cold Spring Harb Perspect Biol (2009) 1.23
Mdm2 induces mono-ubiquitination of FOXO4. PLoS One (2008) 1.22
New frontiers in cell competition. Dev Dyn (2012) 1.21
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 1.20
Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene (2008) 1.16
Suppression of p53 activity by Siva1. Cell Death Differ (2009) 1.14
SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J (2012) 1.12
Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc) (2007) 1.11
Autophagy regulation in cancer development and therapy. Am J Cancer Res (2010) 1.11
Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Res (2013) 1.11
Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem (2008) 1.09
Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer (2012) 1.06
Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One (2012) 1.06
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol (2011) 1.03
Model of human aging: recent findings on Werner's and Hutchinson-Gilford progeria syndromes. Clin Interv Aging (2008) 0.99
Modification of Drosophila p53 by SUMO modulates its transactivation and pro-apoptotic functions. J Biol Chem (2008) 0.97
Downregulation of VRK1 by p53 in response to DNA damage is mediated by the autophagic pathway. PLoS One (2011) 0.95
Hyperoxia impairs alveolar formation and induces senescence through decreased histone deacetylase activity and up-regulation of p21 in neonatal mouse lung. Pediatr Res (2011) 0.94
Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene (2010) 0.94
Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. Breast Cancer Res (2013) 0.93
C/EBPbeta represses p53 to promote cell survival downstream of DNA damage independent of oncogenic Ras and p19(Arf). Cell Death Differ (2008) 0.93
A synthetic-natural hybrid oscillator in human cells. Proc Natl Acad Sci U S A (2010) 0.92
The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response. Nucleic Acids Res (2008) 0.92
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest (2010) 0.91
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Manipulation of gene expression by oxygen: a primer from bedside to bench. Pediatr Res (2009) 0.90
hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J Virol (2008) 0.89
Decision-making by p53 and mTOR. Aging (Albany NY) (2010) 0.89
Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev (2007) 0.89
Differential gene expression in normal and transformed human mammary epithelial cells in response to oxidative stress. Free Radic Biol Med (2011) 0.88
p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization. Am J Physiol Endocrinol Metab (2014) 0.87
Aneuploidy and chromosomal instability: a vicious cycle driving cellular evolution and cancer genome chaos. Cancer Metastasis Rev (2013) 0.87
Levels of pro-apoptotic regulator Bad and anti-apoptotic regulator Bcl-xL determine the type of the apoptotic logic gate. BMC Syst Biol (2013) 0.87
Effects of mutant human Ki-ras(G12C) gene dosage on murine lung tumorigenesis and signaling to its downstream effectors. Toxicol Appl Pharmacol (2008) 0.87
Social isolation reduces mammary development, tumor incidence, and expression of epigenetic regulators in wild-type and p53-heterozygotic mice. Cancer Prev Res (Phila) (2010) 0.87
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One (2012) 0.86
Ubiquitin and ubiquitin-like proteins in the nucleolus: multitasking tools for a ribosome factory. Genes Cancer (2010) 0.86
Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ (2013) 0.86
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget (2013) 0.86
Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics (2013) 0.86
A p53-Pax2 pathway in kidney development: implications for nephrogenesis. PLoS One (2012) 0.86
MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle (2014) 0.86
Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther (2010) 0.85
Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. Oncotarget (2015) 0.84
Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol (2013) 0.84
PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Res (2013) 0.84
Recombinant human MFG-E8 attenuates intestinal injury and mortality in severe whole body irradiation in rats. PLoS One (2012) 0.83
Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells. Mol Med Rep (2014) 0.83
Nested autoinhibitory feedbacks alter the resistance of homeostatic adaptive biochemical networks. J R Soc Interface (2013) 0.82
Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis. Cell Death Differ (2012) 0.81
Stochastic modeling and simulation of the p53-MDM2/MDMX loop. J Comput Biol (2009) 0.81
p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem (2010) 0.81
USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2. Oncogene (2015) 0.81
OTUD5 regulates p53 stability by deubiquitinating p53. PLoS One (2013) 0.80
Regulation of Metabolic Activity by p53. Metabolites (2017) 0.79
The role of chromosome missegregation in cancer development: a theoretical approach using agent-based modelling. PLoS One (2013) 0.79
Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage. Mol Cell Biol (2015) 0.79
Comprehensive Expression Profiling and Functional Network Analysis of p53-Regulated MicroRNAs in HepG2 Cells Treated with Doxorubicin. PLoS One (2016) 0.79
p53 and metabolism: old player in a new game. Transcription (2012) 0.79
Lack of p53 affects the expression of several brain mitochondrial proteins: insights from proteomics into important pathways regulated by p53. PLoS One (2012) 0.79
A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53. J Biol Chem (2010) 0.79
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells. Sci Rep (2015) 0.79
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04
Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 9.57
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08
p14ARF links the tumour suppressors RB and p53. Nature (1998) 4.78
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet (1992) 3.85
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
Role of NF-kappaB in p53-mediated programmed cell death. Nature (2000) 3.62
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell (1991) 3.58
Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol (2001) 3.46
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 3.24
Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol (2000) 3.12
A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol (1989) 3.00
p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene (1991) 2.76
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Regulation of p53 stability. Oncogene (1999) 2.54
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev (1996) 2.26
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J (1996) 2.12
C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol (2001) 2.09
Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell (1994) 2.06
Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol (2000) 2.02
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol (1996) 1.99
Retracted Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet (1989) 1.94
p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J (1991) 1.91
Activation and activities of the p53 tumour suppressor protein. Br J Cancer (2001) 1.90
A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene (2000) 1.85
PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ (2009) 1.83
Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene (1990) 1.76
Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol (1997) 1.73
Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol (1998) 1.69
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene (2012) 1.62
Mdm2 binds p73 alpha without targeting degradation. Oncogene (1999) 1.62
Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci (1999) 1.62
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway. Oncogene (2008) 1.60
Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev (1997) 1.59
Regulation of p53 function. Exp Cell Res (2001) 1.55
Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol (1998) 1.50
Analysis of the degradation function of Mdm2. Cell Growth Differ (1999) 1.49
Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene (1998) 1.41
Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature (1984) 1.40
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J (1992) 1.39
Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene (1996) 1.39
E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell (1999) 1.34
Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog (1991) 1.33
Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene (1994) 1.32
Mutations activating human c-Ha-ras1 protooncogene (HRAS1) induced by chemical carcinogens and depurination. Proc Natl Acad Sci U S A (1986) 1.29
Keeping an old friend under control: regulation of p53 stability. Mol Med Today (1998) 1.29
Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol (2000) 1.28
HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes. EMBO J (1994) 1.28
Analysis of human papillomavirus type 16 open reading frame E7 immortalizing function in rat embryo fibroblast cells. J Gen Virol (1990) 1.28
Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol (2000) 1.27
Regulation and activation of p53 and its family members. Cell Death Differ (1999) 1.27
Status of c-myc, p53 and retinoblastoma genes in human papillomavirus positive and negative squamous cell carcinomas of the anus. Oncogene (1991) 1.26
E2F-1 induced apoptosis. Apoptosis (2001) 1.22
Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb Symp Quant Biol (2011) 1.20
ASPP1 and ASPP2 are new transcriptional targets of E2F. Cell Death Differ (2005) 1.15
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene (1998) 1.15
E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res (1996) 1.14
The ins and outs of p53. Nat Cell Biol (2000) 1.14
Human papillomavirus detection by hybrid capture and its possible clinical use. J Clin Pathol (1994) 1.11
Three different activated ras genes in mouse tumours; evidence for oncogene activation during progression of a mouse lymphoma. EMBO J (1984) 1.07
Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer (1992) 1.06
Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol (1997) 1.06
Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. Cancer Res (1999) 1.05
Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene (1993) 1.03
Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene (1995) 1.02
Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene (1994) 0.99
Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene (1994) 0.99
Functions of human papillomavirus E6 and E7 oncoproteins. Trends Microbiol (1994) 0.98
Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology (1996) 0.96
New HPV E6 binding proteins: dangerous liaisons? Trends Microbiol (1998) 0.96
Reversal of p53-induced cell-cycle arrest. Mol Carcinog (1999) 0.93
Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. J Virol (1991) 0.90
Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2. J Biomol Screen (2004) 0.87
Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. J Gen Virol (1997) 0.87
A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. J Gen Virol (1989) 0.85
Enhanced spontaneous metastasis of mouse carcinoma cells transfected with an activated c-Ha-ras-1 gene. Int J Cancer (1986) 0.85
E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer (2002) 0.84
Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions. Carcinogenesis (2001) 0.83
Activation of p53 DNA binding activity by point mutation. Oncogene (1998) 0.82
Functional analysis of human papillomavirus type 16 E7 by complementation with adenovirus E1A mutants. J Gen Virol (1992) 0.82
Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). Carcinogenesis (1997) 0.80
Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6. Mol Carcinog (1998) 0.79
Interaction of HPV E6 with p53 and associated proteins. Biochem Soc Trans (1994) 0.78
Lack of p53-mediated G1 arrest in response to an environmental carcinogen. Oncology (1999) 0.77
Acetyltransferases and tumour suppression. Breast Cancer Res (2000) 0.75
DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers. Mol Carcinog (1998) 0.75